RESEARCH SUPPORT, NON-U.S. GOV'T
Add like
Add dislike
Add to saved papers

Prescription of walking exercise intensity from the 6-minute walk test in people with chronic obstructive pulmonary disease.

PURPOSE: The 6-minute walk test (6MWT) is widely used in clinical practice, particularly to assess functional exercise capacity and to prescribe walking training intensity in people with chronic obstructive pulmonary disease (COPD). However, the actual walking intensity prescribed from the 6MWT, in terms of percent peak oxygen uptake (%(Equation is included in full-text article.)O2peak) and percent (Equation is included in full-text article.)O2 reserve (%(Equation is included in full-text article.)O2R), has not been previously reported. This study aims to examine the exercise intensity when walking training is prescribed at 80% average 6MWT speed.

METHODS: Patients with COPD (N = 45) were recruited. Peak (Equation is included in full-text article.)O2 from an incremental cycle test and 6MWT and (Equation is included in full-text article.)O2 from a 10-minute walking exercise (Walk-10) were measured by a portable metabolic system (Cosmed K4b; Cosmed, Rome, Italy). Walk-10 was done on the same oval course as the 6MWT. Participants were asked to walk at 80% average 6MWT speed for 10 minutes continuously.

RESULTS: Four participants could not complete Walk-10 and 2 did not perform Walk-10 due to low 6MWT distance. The remaining 39 participants with mean (SD) forced expiratory volume in 1 minute of 58 (19)% predicted completed Walk-10. The mean intensity of Walk-10 was 69 (17)% (Equation is included in full-text article.)O2R or 77 (13)% (Equation is included in full-text article.)O2peak. Steady-state (Equation is included in full-text article.)O2 was achieved within the first 4 minutes of Walk-10.

CONCLUSION: Walking exercise prescribed at 80% average 6MWT speed resulted in a high but tolerable exercise intensity that is likely to result in training benefits in most people with COPD.

Full text links

For the best experience, use the Read mobile app

Group 7SearchHeart failure treatmentPapersTopicsCollectionsEffects of Sodium-Glucose Cotransporter 2 Inhibitors for the Treatment of Patients With Heart Failure Importance: Only 1 class of glucose-lowering agents-sodium-glucose cotransporter 2 (SGLT2) inhibitors-has been reported to decrease the risk of cardiovascular events primarily by reducingSeptember 1, 2017: JAMA CardiologyAssociations of albuminuria in patients with chronic heart failure: findings in the ALiskiren Observation of heart Failure Treatment study.CONCLUSIONS: Increased UACR is common in patients with heart failure, including non-diabetics. Urinary albumin creatininineJul, 2011: European Journal of Heart FailureRandomized Controlled TrialEffects of Liraglutide on Clinical Stability Among Patients With Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial.Review

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

Read by QxMD is copyright © 2021 QxMD Software Inc. All rights reserved. By using this service, you agree to our terms of use and privacy policy.

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app